Something shifted in the pharmacy profession this month that is easy to miss in the daily noise of prescription volume, prior authorization denials, and drug shortages. But when you line up what happened in a single July, the pattern becomes unmistakable.
Nine pharmacy organizations sent a unified letter to HHS about ACIP governance, the largest coalition action the profession has taken on vaccine policy in years. A landmark JAMA study proved that a pharmacist phone call doubles prescriptions of a life-saving drug class in 8,600 patients across eight VA health systems. The Main Street Pharmacy Access Act sits in Congress with more than a quarter of its members already co-sponsoring. The CMS ACCESS Model launched with pharmacists explicitly named as designated coordination points for the four most prevalent chronic conditions in Medicare. All of this happened in July 2026.
That is not a coincidence. It is a threshold moment, and the pharmacists who recognize it as such will respond differently than the ones who experience it as just another busy July.
The JAMA Study That Deserves More Attention Than It Received
The most clinically significant piece of new evidence this month arrived in JAMA Network Open, and it generated far less discussion in pharmacy circles than it warranted.
A quality improvement study across 8 VA health systems evaluated whether proactive pharmacist outreach could increase SGLT2 inhibitor initiation among veterans with type 2 diabetes with a hemoglobin A1C of 7 or greater and chronic kidney disease. Researchers identified more than 8,600 eligible patients using the VA clinical diabetes dashboard. The findings demonstrated that pharmacist outreach doubled SGLT2 inhibitor initiation rates compared to usual care, helping close a significant gap between guideline-directed therapy recommendations and real-world prescribing.
Read that again. Not a trend. Not a signal. Not a promising preliminary finding. Doubled. In 8,600 patients. Across eight health systems. Published in JAMA.
The study didn’t require a new drug. It didn’t require a new clinical protocol. It required a pharmacist, a phone, and a patient who had been waiting for someone to make the call.
The findings suggest that pharmacist-led outreach represents a practical strategy for increasing use of evidence-based therapies in patients with CKD and type 2 diabetes. As evidence supporting the cardiorenal benefits of SGLT2 inhibitors continues to grow, pharmacist-driven population health initiatives may help close the gap between guideline recommendations and real-world prescribing.
This study landed in the same month that the 2026 ADA Standards repositioned SGLT2 inhibitors as core cardiorenal protective therapy irrespective of A1C. The same month the CMS ACCESS Model launched with a CKM track covering type 2 diabetes and CKD. The same month finerenone received Priority Review for its T1D-CKD indication. The convergence of clinical evidence, guideline updates, and payment model innovation all pointing in the same direction in a single month is not random.
What Changed and What It Actually Means
For most of pharmacy’s modern history, the profession has been asking for recognition, asking for reimbursement, asking for scope expansion, and asking payers and policymakers to acknowledge what pharmacists do. That asking has been necessary. It has also been largely unrewarded for decades.
What is different in 2026 is that the asking is being replaced by proving.
The JAMA study didn’t ask anyone to believe pharmacists improve cardiorenal outcomes. It proved it in 8,600 veterans across eight health systems. The CMS ACCESS Model didn’t ask payers to consider pharmacist-led coordination. It built pharmacist coordination into the payment structure of the largest healthcare payer in the country. The Main Street Pharmacy Access Act didn’t ask for provider status in principle. It specified exactly what services would be reimbursed, at exactly what rate, under exactly what clinical conditions.
The PLOS ONE Shields-UMass diabetes coaching study documented 22 fewer hospital admissions per 100 patients. The Geisinger ConnectedCare365 RPM program produced 74% blood pressure control in resistant hypertension. The ACTIV-6 metformin trial halved clinician-diagnosed long COVID. The pharmacist-led biosimilar substitution program across 17 states drove 90-plus percent preferred product uptake. Every one of these stories is the same story: a pharmacist performed a clinical intervention, the outcomes were measured, and the evidence was published.
The profession is shifting from advocacy mode to evidence mode. And that shift changes what the most important thing for an individual pharmacist to do right now actually is.
Evidence Is Now the Currency That Moves Payers and Policymakers
The answer is not to lobby harder. It is to produce outcomes.
Every pharmacist who runs a rigorous GLP-1 adherence monitoring program and documents A1C improvements is producing evidence. Every pharmacist who builds an SGLT2 initiation outreach protocol and tracks the number of prescriptions started is producing evidence. Every pharmacist who facilitates early inhaler refills during a wildfire event and prevents an ER visit is producing evidence. Every pharmacist who calculates a FIB-4 on a diabetic patient and catches advanced liver fibrosis before it becomes cirrhosis is producing evidence.
That evidence, aggregated across thousands of pharmacy practices, moves payers and policymakers faster than any advocacy campaign. The payer who sees data from fifty independent pharmacies documenting that pharmacist-led SGLT2 initiation outreach doubled prescription rates in their own covered population is not responding to a lobbying argument. They are responding to their own financial exposure, calculated from documented outcomes. That is a fundamentally different conversation.
The pharmacist who walks into a value-based contract negotiation with 12 months of documented clinical outcomes, organized by intervention type, outcome measure, and cost avoidance estimate, is having a fundamentally different conversation than the pharmacist who walks in with enthusiasm and a business card. One is asking to be believed. The other is showing the receipts.
The Evidence Infrastructure Most Pharmacies Don’t Have
The gap between pharmacists who produce outcomes and pharmacists who produce evidence is not a gap in clinical competency. It is a gap in documentation infrastructure.
A pharmacist who calls 50 patients about SGLT2 initiation after reviewing their diabetes dashboard performs the same clinical work regardless of whether they track the outcome. The ones who track it document: how many patients were contacted, how many agreed to discuss therapy intensification, how many had a new SGLT2 prescription written within 30 days, how many filled it, and how the prescribing physician responded to the outreach. Six months of that data is a replicable evidence set. Twelve months is a publishable quality improvement study.
The documentation system doesn’t need to be sophisticated. A spreadsheet with six columns is sufficient for a small practice:
Patient identifier (de-identified). Intervention date. Intervention type. Outcome at 30 days. Outcome at 90 days. Notes.
A pharmacist who tracks 100 clinical interventions this way over 12 months has the data architecture for a meaningful outcomes story. A practice with 5 pharmacists each tracking 100 interventions has the data architecture for something a health system or payer will pay to see.
The Specific Interventions With the Strongest Evidence Basis
Five clinical interventions this newsletter has documented throughout 2026 have the strongest combination of existing published evidence and immediate replicability in community or health-system pharmacy settings.
SGLT2 inhibitor initiation outreach for CKD and T2D patients. The JAMA study this month provides direct evidence for a pharmacist-driven population health approach. The documentation system: identify patients using your pharmacy’s diabetes-CKD population filter, track outreach attempts, and record new SGLT2 prescriptions within 30 days of pharmacist contact.
GLP-1 adherence monitoring with A1C tracking. Real-world persistence data for GLP-1 therapy is suboptimal, and the gap between clinical trial weight loss results and real-world outcomes directly reflects adherence failure. The documentation system: track monthly refill status for enrolled GLP-1 patients and A1C at baseline, 6 months, and 12 months.
Medication reconciliation at care transitions. The published literature on pharmacist-led reconciliation is robust. The documentation system: for every discharge medication reconciliation you perform, record the number of medication discrepancies identified, the clinical risk level of each discrepancy, and whether the discrepancy was resolved before patient discharge.
Early inhaler refill during air quality events. The wildfire smoke event documented this issue. The documentation system: when an air quality alert is active, track the number of early refill overrides requested, the number approved, and the number of patients who avoided an emergency visit based on follow-up contact within 14 days.
MASLD FIB-4 screening in the diabetes and obesity panel. The earlier MASLD issue documented that two-thirds of diabetes patients have undiagnosed MASLD. The documentation system: for every FIB-4 calculated, record the score, the patient’s relevant comorbidities, and whether the result prompted a referral.
None of these documentation systems require HIPAA compliance officer review before implementation. Each is a tracking log for your own practice quality improvement data, separate from the patient record. Each can be started today with a spreadsheet.
The Threshold Moment Explained
July 2026 produced more concurrent pharmacy evidence, policy, and payment infrastructure alignment than any single month in the profession’s recent history. That does not mean the work is done. It means the work has changed.
For the past decade, the most important thing a pharmacist could do for the profession’s future was to advocate show up at state legislatures, write letters, call Congressional offices, join advocacy days. That work was necessary, and it produced results, the PBM Reform Act, the Main Street Pharmacy Access Act’s committee passage, ACIP reform pressure. Advocacy built the table. But it is not what fills the seats.
What fills the seats is evidence. What gets pharmacists into value-based care contracts is outcomes documentation. What moves a payer from theoretical acknowledgment of pharmacy value to a contracted performance payment is a pharmacist walking in with 12 months of data showing exactly what their interventions produced.
The threshold the profession just crossed is that the infrastructure for those contracts, the CMS ACCESS Model, the Main Street Pharmacy Access Act’s provider status framework, the RPM billing codes, the deprescribing billing pathway, the Stars quality measure alignment, now exists. The building is built. The question is what evidence you will bring when you walk through the door.
Start collecting yours this week.
Sources: Pharmacy Times (Pharmacist Outreach Doubles SGLT2 Inhibitor Uptake in CKD, July 2026), JAMA Network Open (Pharmacist-Led SGLT2 Inhibitor Initiation Outreach in VA Health Systems, 2026), Pharmacy Times (ADA 2026: The 2026 ADA Standards, A Pharmacist’s Guide to Cardiorenal Risk Reduction, June 2026), CMS (ACCESS Model Launch, July 5, 2026), Drug Topics / APhA (Nine Pharmacy Organizations Joint Letter to HHS Secretary Kennedy, July 9, 2026), NCPA / House Ways and Means Committee (Main Street Pharmacy Access Act HR 3164 Committee Passage, May 21, 2026), PLOS ONE (Amante D et al. Effectiveness of a Pharmacist Diabetes Coaching Program, March 2026), AHA Newsroom (ConnectedCare365 Geisinger Hypertension Study, September 2024), Clinical Infectious Diseases (Bramante CT et al. ACTIV-6 Metformin Long COVID Trial, June 2026)